Accelrys Will Be Easier to Do Business With as Standalone Entity, Says Emkjer | GenomeWeb

With the spin-off of parent company Pharmacopeia’s drug discovery business slated to take place at the end of the quarter, Accelrys faces an entirely different future as a standalone software shop — one that will ultimately benefit the company’s customers, employees, partners, and investors, according to Mark Emkjer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.